Tularemia in Pediatric Patients: A Case Series and Review of the Literature.
Journal
The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858
Informations de publication
Date de publication:
23 Sep 2024
23 Sep 2024
Historique:
medline:
23
9
2024
pubmed:
23
9
2024
entrez:
23
9
2024
Statut:
aheadofprint
Résumé
Unfamiliar to pediatricians, tularemia can lead to delays in diagnosis and hinder appropriate treatment, as its clinical presentation often shares similarities with other more prevalent causes of lymphadenopathy diseases in children. We conducted a comprehensive literature review to offer contemporary insights into the clinical manifestations and treatment strategies for tularemia infection in children. Three cases of glandular tularemia were diagnosed in the Pediatric Robert Debré Hospital (Paris) between October 2020 and February 2022. In addition, we conducted a literature search using PubMed in December 2023 of cases of tularemia in children published in English. The 94 cases of the literature review highlight the large age range (from 6 weeks to 17 years) and multiple sources of infection, including diverse zoonotic transmission (86.7%) and contact with contaminated water (13.3%). Fever was a consistent symptom. Ulceroglandular (46.7%), glandular (17%) and oropharyngeal forms (18.1%) predominated. The most frequently used diagnostic method was serology (60.6%). The median time to diagnosis for tularemia was 23.5 days. Hospitalization was required in 63.2% of cases, with a median duration of 4 days. Targeted treatment was based on aminoglycosides (37.6%), fluoroquinolones (30.6%) or tetracyclines (12.9%), in accordance with WHO recommendations, with a mainly favorable outcome, although several cases of meningitis were observed. Pediatricians should be aware of the etiology of this febrile lymphadenopathy, notably when experiencing beta-lactam treatment failure, even in young infants, which could help reduce the extra costs associated with inappropriate antibiotic use and hospitalization.
Sections du résumé
BACKGROUND
BACKGROUND
Unfamiliar to pediatricians, tularemia can lead to delays in diagnosis and hinder appropriate treatment, as its clinical presentation often shares similarities with other more prevalent causes of lymphadenopathy diseases in children. We conducted a comprehensive literature review to offer contemporary insights into the clinical manifestations and treatment strategies for tularemia infection in children.
METHODS
METHODS
Three cases of glandular tularemia were diagnosed in the Pediatric Robert Debré Hospital (Paris) between October 2020 and February 2022. In addition, we conducted a literature search using PubMed in December 2023 of cases of tularemia in children published in English.
RESULTS
RESULTS
The 94 cases of the literature review highlight the large age range (from 6 weeks to 17 years) and multiple sources of infection, including diverse zoonotic transmission (86.7%) and contact with contaminated water (13.3%). Fever was a consistent symptom. Ulceroglandular (46.7%), glandular (17%) and oropharyngeal forms (18.1%) predominated. The most frequently used diagnostic method was serology (60.6%). The median time to diagnosis for tularemia was 23.5 days. Hospitalization was required in 63.2% of cases, with a median duration of 4 days. Targeted treatment was based on aminoglycosides (37.6%), fluoroquinolones (30.6%) or tetracyclines (12.9%), in accordance with WHO recommendations, with a mainly favorable outcome, although several cases of meningitis were observed.
CONCLUSION
CONCLUSIONS
Pediatricians should be aware of the etiology of this febrile lymphadenopathy, notably when experiencing beta-lactam treatment failure, even in young infants, which could help reduce the extra costs associated with inappropriate antibiotic use and hospitalization.
Identifiants
pubmed: 39312633
doi: 10.1097/INF.0000000000004554
pii: 00006454-990000000-01024
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors have no funding or conflicts of interest to disclose.
Références
Mccoy GW, Chapin CW. Further observations on a plague-like disease of rodents with a preliminary note on the causative agent, bacterium Tularense. J Infect Dis. 1912;10:61–72.
Jacobs RF, Condrey YM, Yamauchi T. Tularemia in adults and children: a changing presentation. Pediatrics. 1985;76:818–822.
Yeni DK, Büyük F, Ashraf A, et al. Tularemia: a re-emerging tick-borne infectious disease. Folia Microbiol. 2021;66:1–14.
Wetzstein N, Kärcher I, Küpper-Tetzel CP, et al. Clinical characteristics in a sentinel case as well as in a cluster of tularemia patients associated with grape harvest. Int J Infect Dis. 2019;84:116–120.
Sandström G, Sjöstedt A, Forsman M, et al. Characterization and classification of strains of Francisella tularensis isolated in the central Asian focus of the Soviet Union and in Japan. J Clin Microbiol. 1992;30:172–175.
Peker E, Ayaydin A, Duran N. FAMILIAL TULARAEMIA. Indian J Med Microbiol. 2009;27:272–275.
Ellis J, Oyston PCF, Green M, et al. Tularemia. Clin Microbiol Rev. 2002;15:631–646.
Imbimbo C, Karrer U, Wittwer M, et al. Tularemia in children and adolescents. Pediatr Infect Dis J. 2020;39:e435–e438.
Gunnell MK, Adams BJ, Robison RA. The genetic diversity and evolution of Francisella tularensis with comments on detection by PCR. Curr Issues Mol Biol. 2016;18:79–91.
Hestvik G, Warns-Petit E, Smith LA, et al. The status of tularemia in Europe in a one-health context: a review. Epidemiol Infect. 2015;143:2137–2160.
Janse I, Van Der Plaats RQJ, De Roda Husman AM, et al. Environmental surveillance of zoonotic Francisella tularensis in the Netherlands. Front Cell Infect Microbiol. 2018;8:140.
Mailles A, Vaillant V. 10 years of surveillance of human tularaemia in France. Euro Surveill. 2014;19:20956.
Maurin M, Pelloux I, Brion JP, et al. Human tularemia in France, 2006-2010. Clin Infect Dis. 2011;53:e133–e141.
Celebi S, Hacimustafaoglu M, Gedikoglu S. Tularemia in children. Indian J Pediatr. 2008;75:1129–1132.
European Centre for Disease Prevention and Control. Tularaemia. In: ECDC. Annual epidemiological report for 2019. Stockholm: ECDC; 2021.
Schöbi N, Agyeman PKA, Duppenthaler A, et al. Pediatric tularemia—a case series from a single center in Switzerland. Open Forum Infect Dis. 2022;9:ofac292.
Buckingham SC. Tick-borne diseases of the USA: ten things clinicians should know. J Infect. 2015;71(Suppl 1):S88–S96.
Asano S. Granulomatous lymphadenitis. J Clin Exp Hematop. 2012;52:1–16.
Brunet CD, Hennebique A, Peyroux J, et al. Presence of Francisella tularensis subsp. holarctica DNA in the Aquatic Environment in France. Microorganisms. 2021;9:1398.
Hennebique A, Peyroux J, Brunet C, et al. Amoebae can promote the survival of Francisella species in the aquatic environment. Emerg Microbes Infect. 2021;10:277–290.
Tärnvik A, Berglund L. Tularaemia. Eur Respir J. 2003;21:361–373.
Hanke CA, Otten J-E, Berner R, et al. Ulceroglandular tularemia in a toddler in Germany after a mosquito bite. Eur J Pediatr. 2009;168:937–940.
Abdellahoum Z, Maurin M, Bitam I. Tularemia as a mosquito-borne disease. Microorganisms. 2020;9:26.
Jounio U, Renko M. [Tularemia as a pediatric problem]. Duodecim. 2009;125:1511–1515.
Maurin M. Francisella tularensis, Tularemia and serological diagnosis. Front Cell Infect Microbiol. 2020;10:512090.
World Health Organization. WHO Guidelines on tularaemia. 2007:115.
Maurin M, Gyuranecz M. Tularaemia: clinical aspects in Europe. Lancet Infect Dis. 2016;16:113–124.
Johansson A, Berglund L, Eriksson U, et al. Comparative analysis of PCR versus culture for diagnosis of ulceroglandular Tularemia. J Clin Microbiol. 2000;38:22–26.
Tang KWK, Millar BC, Moore JE. Antimicrobial resistance (AMR). Br J Biomed Sci. 2023;80:11387.
Antunes NT, Frase H, Toth M, et al. The class A β-lactamase FTU-1 is native to Francisella tularensis. Antimicrob Agents Chemother. 2012;56:666–671.
Cross JT, Jacobs RF. Tularemia: treatment failures with outpatient use of ceftriaxone. Clin Infect Dis. 1993;17:976–980.
Johansson A, Urich SK, Chu MC, et al. In vitro susceptibility to quinolones of Francisella tularensis subspecies tularensis. Scand J Infect Dis. 2002;34:327–330.
Johansson A, Berglund L, Gothefors L, et al. Ciprofloxacin for treatment of tularemia in children. Pediatr Infect Dis J. 2000;19:449–453.
Caspar Y, Maurin M. Francisella tularensis susceptibility to antibiotics: a comprehensive review of the data obtained in vitro and in animal models. Front Cell Infect Microbiol. 2017;7:122.
Bossi P, Tegnell A, Loock F, et al. Recommandations Bichat sur la prise en charge clinique des patients présentant une tularémie liée ou non à un acte de bioterrorisme. Available at: https://www.eurosurveillance.org/content/10.2807/esm.09.12.00503-fr#metrics_content.
doi: 10.2807/esm.09.12.00503-fr
Pérez-Castrillón JL, Bachiller-Luque P, Martín-Luquero M, et al. Tularemia epidemic in Northwestern Spain: clinical description and therapeutic response. Clin Infect Dis. 2001;33:573–576.
Tezer MS, Övet G, Alataş N, et al. Clinical manifestations of 16 oropharyngeal tularemia patients: experience of a referral hospital in the city of Konya, Turkey. Turk J Med Sci. 2013;43:227–231.
Gozel MG, Engin A, Altuntas EE, et al. Evaluation of clinical and laboratory findings of pediatric and adult patients with oropharyngeal tularemia in Turkey: a combination of surgical drainage and antibiotic therapy increases treatment success. Jpn J Infect Dis. 2014;67:295–299.
Nemmour A, Bakri A, Fischer CA, et al. Paediatric oropharyngeal tularaemia requiring surgical intervention. BMJ Case Rep. 2019;12:e229754.